Rett Syndrome In Pediatric And Adult Patients Therapeutics
1. Daybue patent expiration
Treatment: Treatment of rett syndrome or a symptom thereof
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11827600 | ACADIA PHARMS INC | Crystalline forms of trofinetide |
Jul, 2042
(16 years from now) | |
| US11370755 | ACADIA PHARMS INC | Compositions of trofinetide |
Aug, 2040
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9212204 | ACADIA PHARMS INC | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid |
Jan, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2028 |
| Orphan Drug Exclusivity(ODE-425) | Mar 10, 2030 |
Drugs and Companies using TROFINETIDE ingredient
NCE-1 date: 11 March, 2027
Market Authorisation Date: 10 March, 2023
Dosage: SOLUTION
More Information on Dosage
DAYBUE family patents
